Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year. The post Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder appeared first on MedCity News.

As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care?  The post When AI Gets Medicine Wrong, Who’s Liable? appeared first on MedCity News.

As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change. The post Fifty Years of Pediatric Rheumatology, but Children Still Can’t Access the Treatments They Need appeared first on MedCity News.

What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem.   The post MedTech Commercialization Gap: Moving Beyond Technical Viability  appeared first on MedCity News.

When drug prices are too high for patients, physicians take on additional workload to find solutions. A newly released 2026 Physician Drug Cost Survey by RazorMetrics examined how prescription cost pressures affect physicians’ practices. The post Report: High Drug Costs Are Creating Hidden Burden for Physicians appeared first on MedCity News.

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary angioedema, and the RNA therapies pipeline also spans immunological disorders, cardiovascular diseases and obesity, and neurodegeneration. The post Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut appeared first on MedCity News.

The question is whether these AI tools will be another fragmented layer of technology or true assistants to help them spend more time on patient care.  The post AI Goes All In To Support Nursing Teams: Ambient Charting is Just the Start appeared first on MedCity News.

CertifyOS launched a shared credentialing program that allows providers to submit their information once for multiple health plans. The post UHC, Cigna and Centene Sign On to New National Shared Credentialing Program appeared first on MedCity News.

Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare specializes in oncology and autoimmune drugs. The post Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact appeared first on MedCity News.

Healthcare has a habit of embracing patient empowerment right up until patients become powerful. The post From OpenNotes to “Doc Can I Record You?” Why Physicians Should Embrace Era of Accountability appeared first on MedCity News.

The Centers for Medicare & Medicaid Services (CMS) took constructive steps in its 2027 final rule and rate announcement, particularly on payment integrity and quality measurement. But those steps are not the finish line. Policymakers should further modernize MA to strengthen competition, transparency and accountability. Here’s where to start. The post Modernizing Medicare Advantage for the Next Generation of Seniors appeared first on MedCity News.

Roche reported the drug sefaxersen achieved statistically significant and clinically meaningful results in a Phase 3 test in immunoglobulin A nephropathy, or IgAN. This antisense oligonucleotide, which came from Ionis Pharmaceuticals, could offer advantages over other drugs currently available for treating this rare chronic disease of the kidneys. The post Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease` appeared first on MedCity News.

The Series A round was led by .406 Ventures, with support from Emerson Collective (managed by Yosemite), Forerunner, Serena Ventures and Japan-based MPower Partners. The post Teal Health Secures $22M for At-Home HPV Cervical Cancer Screening Device appeared first on MedCity News.

At the annual South Asian Health Leaders Forum held in Boston last week, Shiv Rao talked candidly about his biography and how it propelled him to build Abridge The post Who is Abridge’s CEO Shiv Rao? No, Really… appeared first on MedCity News.

Years of joint industry-academic engineering suggest that highly engineered single agents will not be the most effective treatments for solid tumors; the solution will be combining the right drugs and administering them in the right way. The post Innovation in Oncology: The Synergy of New and Old Drugs appeared first on MedCity News.